Table 1.

Baseline characteristics of all biologic-naïve PsA patients treated with their first TNFi and available DAS28-CRP at 6 month, data pooled across all countries

FemaleMale
Mean (SD), median [IQR] or percentagesMean (SD), median [IQR] or percentages
Age (years)49.7 (12.5)47.8 (11.9)
Disease duration (years)4.0 [1.0, 10.0]4.0 [1.0, 10.0]
TNFi start year
 1999-200929%29%
 2010-201326%27%
 2014-201625%24%
 2017-202020%20%
Concomittant csDMARD75%77%
DAS28-CRP4.4 (1.2)4.2 (1.2)
DAPSA2832 (16)29 (16)
CRP (mg/L)7.0 [3.0, 17.0]8.0 [3.3, 19.0]
SJC (0-28)3.0 [1.0, 6.0]3.0 [1.0, 6.0]
TJC (0-28)6.0 [2.0, 10.0]4.0 [2.0, 9.0]
VAS pain, mm61 (23)55 (23)
VAS fatigue, mm62 (26)53 (27)
  • Data are as observed, mean (SD), median [IQR] or percentage. TNFi, tumor necrosis factor inhibitor; csDMARD, Conventional synthetic disease-modifying antirheumatic drugs; DAS28-CRP, Disease Activity Score 28-joint count C reactive protein; DAPSA28, Disease Activity in PsA 28; CRP, C-reactive protein; SJC, swollen joint count; TJC, tender joint count.